WHO ICTRP trial
To evaluate the adjuvant potential of methotrexate in mucosal/ limited…
CTRI/2018/07/015002 · Clinical Trials Registry India (CTRI) · Recruiting
Key facts
| Trial ID | CTRI/2018/07/015002 |
|---|---|
| Public title | To evaluate the adjuvant potential of methotrexate in mucosal/ limited mucocutaneous pemphigus vulgaris |
| Scientific title | A randomised trial of prednisolone and methotrexate Vs prednisolone alone to assess the adjuvant potential of methotrexate in mucosal/ limited mucocutaneous pemphigus vulgaris |
| Primary sponsor | PGIMER |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | India |
| Conditions | Health Condition 1: null- mucosal or limited mucocutaneous pemphigus vulgaris (less than 5% BSA) Health Condition 2: L100- Pemphigus vulgaris |
| Interventions | Intervention1: methotrexate & prednisolone: Prednisolone will be prescribed at a dose of 1 mg/kg/day (rounded off to nearest multiple of 5, upto a maximum dosage of 80 mg/day) in a single morning dose and methotrexate will be given at a… |
| Registration date | Jul 23, 2018 |
| Target size | 30 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: